Kornimate/medical-research-clean huggingface dataset:
anterior chamber illumination in cataract surgery for eyes with poor red reflex

Conditions: Cataract Senile

Summary: with a poor red reflex, it is difficult to see the anterior capsule and continuous curvilinear capsulorhexis (ccc) margin, sometimes resulting in decentered ccc or radial tearing of the anterior capsule. in addition, other complications, such as rupture of the posterior capsule, dropping of the lens nucleus, or zonular dialysis, can occur during phacoemulsification because of poor visualization of the posterior capsule. these complications also increase the time of surgery and may affect the results of the vitrectomy.

several surgical techniques have been used to alleviate the problem of poor lens visibility. fixed a chandelier illuminator on the sclera, turned off the microscope light source, and visualized the lens by illuminating the vitreous cavity. furino improved anterior lens capsule visibility by staining it with triamcinolone acetonide. although both techniques were effective, both had limitations. vitreous chamber illumination reduces the visibility of the cornea and iris because of the need to turn off the microscope light. staining the anterior lens capsule with triamcinolone acetonide allows for better anterior chamber visualization but the lenticular nucleus and cortex remain difficult to see. this will be a prospective interventional case series, patients with cataract and poor red reflex will undergo phacoemulsification assisted by anterior chamber illumination to overcome the problem of poor red reflex.

Eligibility criteria:
inclusion criteria: * cataract with poor red reflex exclusion criteria: * eyes that had previous intraocular surgery or trauma were excluded.
treatment of cnv with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega-3

Conditions: Macular Edema

Summary: to determine whether a combination of intravitreal aflibercept and pranoprofen eyedrops or nutraceutical support provides additional benefit over iva monotherapy for the treatment of choroidal neovascularization in age-related macular degeneration.


Eligibility criteria:
inclusion criteria: * provision of written informed consent and compliance with study assessments for the full duration of the study * age \> 40 years * presence of treatment-naïve neovascular amd. exclusion criteria: * any previous intravitreal treatment * previous laser treatment in the study eye * myopia \> 7 diopters in the study eye * concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy and advanced glaucoma) * concurrent corneal epithelial disruption or any condition that would affect the ability of the cornea to heal * known sensitivity to any component of the formulations being investigated.
safety and efficacy of lcl161 in patients with solid tumors

Conditions: Advanced Solid Tumors

Summary: the study will evaluate the safety of increasing doses of oral lcl161 in patients with solid tumors. it is primarily designed to evaluate the side effects and find the maximum tolerated dose of lcl161.


Eligibility criteria:
inclusion criteria: * solid tumor * ecog performance status 0-2 * life expectancy greater than or equal to 12 weeks * must meet certain blood laboratory values * must meet criteria for time since the last dose of prior therapy * must provide written informed consent to participate in this study exclusion criteria: * active and/or symptomatic brain tumors or brain metastases. * patients with unresolved nausea, vomiting, or diarrhea * any ongoing severe and/or uncontrolled medical condition that could compromise participation in the study including heart, lung or inflammatory disease * any disease that may significantly alter the absorption of the study drug (for example, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or removal of small bowel) * patients who are currently receiving treatment with steroids at a certain dose or other immunosuppressive treatment that cannot be stopped prior to starting study drug * patients who are currently receiving treatment with certain medications * patients who have received radiation therapy or have undergone major surgery within the last 4 weeks * women of child-bearing potential who are pregnant or breast feeding. * known diagnosis of human immunodeficiency virus (hiv) infection or chronic active hepatitis b or c * patients unwilling or unable to follow the protocol other protocol-defined inclusion/exclusion criteria may apply

Keywords: cancer adults solid tumor apoptosis programmed cell death lcl161
confocal laser endomicroscopy

Conditions: Digestive System Diseases

Summary: confocal laser endomicroscopy (cle) is a new diagnostic technique that allows microscopic examination of the digestive mucosa during ongoing endoscopy. different types of tissue and diseases can be diagnosed immediately, and analysis of the in vivo microarchitecture is helpful to better target standard biopsies and reduce the number of biopsies required. cle necessitates an intravenous injection of a fluorescent marker, e.g. fluorescein, to obtain 'optical biopsies' with a high level of magnification (up to 1000 fold). to date, more than 1000 endomicroscopy procedures have been performed in the world and different publications have shown the safety, feasibility and excellent diagnostic yield of cle. no complication related to iv injection of fluorescein has been reported. however, all these data come from a very limited number of expert centres and need to be confirmed and validated at the multicenter level. the aims of this multicenter trial are: 1) to standardize cle in all centres equipped in france, 2) to ensure the safety of intravenous fluorescein injection, 3) to test the diagnostic value of cle in various conditions representative of the large spectrum of different cancerous and non-cancerous digestive diseases.


Eligibility criteria:
inclusion criteria: * patient between 18 to 70 years-old * symptoms or disease requiring an upper gi endoscopy or a colonoscopy performed under general anaesthesia * written informed consent obtained exclusion criteria: * no indication for upper gi endoscopy or colonoscopy * treatment by beta-blockers * coagulopathy * dialysis for impaired renal function * pregnancy or breast-feeding * known allergy to fluorescein * pace-maker * severe cardiac or liver disease * emergency context- zenker's diverticulum (for upper gi endoscopy) or recently complicated colonic diverticulosis (for colonoscopy) * patient's refusal

Keywords: confocal laser endomicroscopy cancerous and non-cancerous conditions tolerance intravenous fluorescein digestive symptoms or disease requiring an endoscopy procedure (upper gi endoscopy or colonoscopy) performed under general anaesthesia
efficacy and safety study of eravacycline compared with levofloxacin in complicated urinary tract infections

Conditions: cUTI

Summary: this is a phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy and safety of eravacycline compared with levofloxacin in participants with complicated urinary tract infections (cuti).

this study began with a 3-arm lead-in portion to determine the oral (po) dosing (200 or 250 milligrams \[mg\]) of eravacycline to be used with intravenously (iv) administered eravacycline for the pivotal portion (2 arms). a po dose of 200 mg was selected based on the unblinded lead-in analysis.

Eligibility criteria:
inclusion criteria: 1. male and female participants with either: a. pyelonephritis and normal urinary tract anatomy (approximately 50% of the total population), or b. cuti with at least 1 of the following conditions associated with a risk for developing cuti: i. indwelling urinary catheter ii. urinary retention (approximately 100 milliliters of residual urine after voiding) iii. neurogenic bladder iv. partial obstructive uropathy (such as, nephrolithiasis, bladder stones, and ureteral strictures) v. azotemia of renal origin (not congestive heart failure or volume related) such that the serum blood urea nitrogen (bun) is elevated (\>20 mg/deciliters) and the serum bun: creatinine ratio is \<15 vi. surgically modified or abnormal urinary tract anatomy (such as, bladder diverticula, redundant urine collection system) except surgery within the last month exclusion criteria: 1. concurrent use of non-study antibacterial drug therapy that would have a potential effect on outcome evaluations in participants with cuti, including: 1. participants with a history of a levofloxacin-resistant urinary tract infection 2. likely to receive ongoing antibacterial drug prophylaxis prior to the late post-treatment visit (such as, participants with vesiculo-ureteral reflux)
text message reminders for influenza vaccine in pregnancy

Conditions: Pregnancy

Summary: influenza virus accounts for numerous cases (epidemics) of respiratory illnesses each year worldwide and affects people of all ages. these epidemics typically occur in the winter months, and can result in substantial morbidity and mortality in persons at risk. pregnant women may be more susceptible to morbidity and mortality associated with influenza infection. this increased risk may result from several factors including increased heart rate, stroke volume, and oxygen consumption, decreased lung capacity, and changes in immunologic function. immunization of women during pregnancy can help to prevent infection in the woman herself and may also offer protection to the infant in two ways: by the passage of antibodies from mother to the fetus during pregnancy, and by preventing infection in the mother and therefore decreasing the infant's exposure risk after birth. in canada, the national advisory committee on immunization (naci) recommends the vaccine for pregnant women who are expected to deliver during influenza season because they will become household contacts of their newborn. ideal timing of vaccination occurs in october or november since influenza outbreaks typically occur throughout the winter months. despite the canadian and american guidelines for influenza vaccination during pregnancy, it is unclear how many women are offered and/or actually receive the vaccine while pregnant. there is, however, evidence that women will accept the vaccine if offered. specifically, in the women's health care centre at st. michael's hospital, it was found that 42% of women not only accepted but also received the influenza vaccination when offered. innovative techniques will be required to continue to increase vaccination rates among vulnerable populations, including pregnant women. the purpose of the present study is to determine if the use of electronic reminders (text messages) increases the likelihood of receiving the influenza vaccine among pregnant women.


Eligibility criteria:
inclusion criteria: * pregnant woman * ages 18 and over * working cellular telephone with the ability to receive text messages * ability to speak or understand english exclusion criteria: * age less than 18 * inability to speak or understand english * not possessing a working cellular telephone with text messaging capability * presence of any contraindications to vaccination (such as egg allergy or prior adverse reaction to the vaccine) * women who have already received the vaccine during this influenza season

Keywords: influenza vaccine text message
a study assessing the effect of ro4607381 on vascular function in patients with coronary heart disease (chd) or chd-risk equivalent patients

Conditions: Coronary Heart Disease

Summary: this study will assess the safety, tolerability and efficacy of ro4607381 in patients with coronary heart disease (chd) or chd risk equivalents. patients will be randomized to receive either ro4607381 600mg po daily or placebo po daily. endothelial function will be measured by flow mediated dilatation and blood pressure monitoring will be assessed. the anticipated time on study treatment is up to 12 months, and the target sample size is up to 500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-75 years of age; * chd or chd risk equivalent; * appropriately treated for accepted ldl-c level. exclusion criteria: * treatment with drugs raising hdl-c (eg niacin, fibrates); * uncontrolled hypertension; * recent (within 3 months) clinically significant coronary events, transient ischemic attacks or cerebrovascular accident; * severe anemia; * poorly controlled diabetes.
comparative study on the effect of quadratus lumborum block versus intrathecal morphine on the incidence of chronic pain post caesarean section in a university hospital of middle-income country

Conditions: Chronic Post Cesarean Pain

Summary: the aim of this study is to compare the incidence of cpscp in patients receiving qlb quadratus lumborum block and itm versus control as a primary outcome and associated risk factors that might predispose patients to develop cpscp.

the aim of this study is to compare the incidence of chronic post cesarean pain in patients receiving quadratus laborum block and and intrathecal morphine versus control as a primary study design: patients will be randomly allocated to the procedure through closed envelopes and so syringes and medication will be prepared and labelled by anesthetist other than the anesthetist giving the block patients will be randomly allocated to the procedure through closed envelopes and so syringes and medication will be prepared and labelled by anesthetist other than the anesthetist giving the block data will be collected regarding the demographic data, gestational stage, parity and number of previous cesarean section, previous abdominal surgeries, and narcotic consumption. postoperative pain day 1 and day2 will be followed by anesthetist who is blinded to the applied technique used. follow up for the subsequent period of observation (2,4and 6 months) will be done by the department secretary who will contact the patients by phone to ask them if there is any "concern" after the operation. if the patient refers to a pain at the surgical site that has been lasting for the past three months a call will be conducted by the anesthetist and a referral schedule will be appointed to the pain clinic consultant for further evaluation

Eligibility criteria:
inclusion criteria: * patients admitted to the operating theatre for elective caesarean section exclusion criteria: * lack of informed consent * allergy to drugs used during the study * depression and epilepsy that required antidepressants or anticonvulsants * known coagulopathy as a contraindication for spinal anesthesia
sevoflurane decreases the risk of postoperative delirium after cerebral hypoxemia during surgery

Conditions: Cerebral Hypoxia; Postoperative Delirium

Summary: the aim of this study is to distinguish possible differences in frequency of delirium after volatile induction and maintenance of anesthesia and total intravenous anesthesia in case of undeliberate cerebral desaturation during non-cardiac surgery.

the aim of the present study is to investigate whether in non-cardiac surgery the frequency of pod after intraoperative undeliberate cerebral saturation could be modulated by the choice of the anesthetic strategy (volatile induction and maintenance of anesthesia \[vima\] and total intravenous anesthesia \[tiva\]). based on our previous data we hypothesized that incidence of pod would be lower with vima compared to tiva.

Eligibility criteria:
inclusion criteria: * class iii-iv by physical status classification system of american society of anesthesiologist (asa) * history of arterial vascular disease (arterial hypertension, myocardial ischemia and/or cerebral vascular disease) * undergoing elective non-cardiac surgery (hemicolectomy, hernioplasty, laparoscopic cholecystectomy and laparoscopic hysterectomy) exclusion criteria: * dementia * stroke or myocardial infarction ≤ 6 months before surgery * oncological disease of t2-4n3m1 stage

Keywords: delirium hypoxic brain damage propofol s100b protein sevoflurane
co-administration of low dose hcg at the time of gnrh agonist trigger or 35 hours later for the prevention of ohss

Conditions: Ovarian Hyperstimulation Syndrome

Summary: this a prospective randomized double blind study involving patients at high risk of ohss development with peak serum e2 levels \< 4,000 pg/ml comparing the ongoing pregnancy rates in patients who receive adjuvant hcg 1,000 iu at the time of gnrh agonist trigger or adjuvant hcg 1,500 iu 35 hours after gnrh agonist trigger.

ovarian hyperstimulation syndrome (ohss) is an iatrogenic complication of controlled ovarian hyperstimulation which may result in significant morbidity and rarely mortality as well as significant financial and psychological distress. gnrh agonist trigger has been shown to be effective in ohss prevention. however, the adoption of its use has not been widely accepted in view of concerns regarding potential impairment of implantation. intensive luteal phase supplementation with estrogen (e2) and progesterone (p) is important due to the strong evidence of abnormal luteal phase serum e2 and p profiles. however, it has been shown that optimal conception rates is not achieved for high risk patients with peak serum e2 \< 4,000 pg/ml despite aggressive steroidal supplementation. it has been proposed that the use of adjuvant low dose hcg at the time of gnrh agonist trigger or 35 hours later will rescue some of the corpora lutea and help improve corpora lutea function and improve pregnancy rates. the study will evaluate patients at high risk of ohss development with peak serum e2 \< 4,000 pg/ml to determine whether timing of low dose hcg administration affects ongoing pregnancy rates or risk of ohss. markers of corpus luteum function such as serum 17 hydroxy-progesterone and prorenin during the luteal phase and early pregnancy will help elucidate further the effect of adjuvant low dose hcg with gnrh agonist trigger on corpus luteum function.

Eligibility criteria:
inclusion criteria: * normal baseline serum follicle stimulating hormone, polycystic ovarian syndrome (pcos), polycystic ovarian morphology, previous high responder or previous ohss, must have \> 14 follicles of over 11 mm in diameter and with peak serum e2 levels \< 4,000 pg/ml on the day of trigger of oocyte maturation. exclusion criteria: * hypothalamic dysfunction, patients with \ = 4,000 pg/ml.

Keywords: ohss, gnrh agonist trigger, low dose hcg, pcos, ivf
study on susceptibility genes of anterior cruciate ligament, patella dislocation and discoid meniscus

Conditions: Gene Abnormality; Meniscus Injury; Cruciate Ligament Rupture

Summary: genomes of all sports medicine-related genes will be exome sequenced to find relevant gene mutations. to further study the molecular mechanisms and signaling pathways related to sports injury. to search for genetic risk factors of injury and put forward related scientific hypotheses. to demonstrate the importance of mutation or polymorphism of related genes in injury.


Eligibility criteria:
inclusion criteria: 1. patients with joint sports injuries. 2. follow-up patients after sports injury. 3. patients with genetic predisposition to sports injuries. 4. patients with family genetic predisposition to exercise-related diseases and their relatives. exclusion criteria: 1. patients with joint damage caused by external force. 2. the patient is accompanied by other injuries at the same time.

Keywords: gene exon cruciate ligament patellar meniscus injury
study investigating immunological effects of treatment for chronic hepatitis c patients.

Conditions: Hepatitis C; Liver; Immunology; Regulation

Summary: aim to evaluate the effects of peginterferon and ribavirin therapy on the immune response in chronic hcv genotype 1,2 or 3 patients before, during and after treatment. background treatment of chronic hepatitis c (hcv) has shown a remarkable success. however, genotype 1 patients have reduced response rates. a better understanding and improvement of these results can now be considered the greatest challenge. in chronically infected patients, hcv-specific immune responses are generally weak, narrowly focused, and often dysfunctional. the presence of hcv-specific cells suppressing the immune response (regulatory t-lymphocytes=treg) are able to suppress the immune response. these treg are possibly responsible for the impaired immune response. previous studies have indicated increased treg frequency and activity of immune regulating mechanisms, locally in the liver, as a result of hcv re-infection. hence, these data highlight the importance of monitoring intrahepatic immune responses in addition to peripheral immune responses. using the minimally-invasive technique of fine-needle aspiration biopsy (fnab), it is now possible to obtain safe and frequent liver samples to monitor local antiviral immune responses in chronic hcv patients during antiviral therapy. rationale and hypothesis of the study our previous studies and current literature support the concept that treg may contribute to hcv persistence by suppressing hcv-spec immune responses. the current study is designed to examine if peginterferon and ribavirin therapy affects the activity of treg and dc, and if this results in enhanced hcv-specific immune responses. design single centre, translational and observational open label study with one arm of 20 genotype 1 patients and one arm of 7 genotype 2/3 patients.


Eligibility criteria:
inclusion criteria: * male and female patients between 18-70 years of age, with evidence of a chronic hepatitis c - genotype 1,2 or 3 infection. * no previous treatment with, peginterferon or conventional interferon plus ribavirin combination therapy. * indication for antiviral therapy of hepatitis c according to current clinical guidelines. * written informed consent. exclusion criteria: * history or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigators, unsuitable for the study. * presence of contra-indications for antiviral therapy with peginterferon or ribavirin.

Keywords: hepatitis c liver immunology regulation genotype 1,2,3 treatment chronic pegylated interferon ribavirin